Tsuyoshi Yokoi

List of Publications by Citations

238 papers	11,161 citations	60 h-index	92 g-index
244 ext. papers	12,094 ext. citations	4.2 avg, IF	6.19 L-index

#	Paper	IF	Citations
238	Near completely humanized liver in mice shows human-type metabolic responses to drugs. *American Journal of Pathology*, **2004**, 165, 901-12	5.8	453
237	Cytochrome P450-mediated metabolism of estrogens and its regulation in human. *Cancer Letters*, **2005**, 227, 115-24	9.9	407
236	MicroRNA regulates the expression of human cytochrome P450 1B1. *Cancer Research*, **2006**, 66, 9090-8	10.1	335
235	Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. *Drug Metabolism and Disposition*, **2008**, 36, 1461-4	4	224
234	Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. *Journal of Biological Chemistry*, **2008**, 283, 9674-80	5.4	219
233	Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. *Protein Expression and Purification*, **2002**, 24, 329-37	2	201
232	Human CYP1B1 is regulated by estradiol via estrogen receptor. *Cancer Research*, **2004**, 64, 3119-25	10.1	200
231	Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. *Drug Metabolism and Disposition*, **2009**, 37, 1759-68	4	190
230	Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. *Clinical Pharmacology and Therapeutics*, **2006**, 80, 282-97	6.1	175
229	MicroRNA regulates human vitamin D receptor. *International Journal of Cancer*, **2009**, 125, 1328-33	7.5	160
228	A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. *Drug Metabolism and Pharmacokinetics*, **2015**, 30, 30-51	2.2	147
227	The emerging role of human esterases. *Drug Metabolism and Pharmacokinetics*, **2012**, 27, 466-77	2.2	144
226	Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. *Archives of Toxicology*, **2002**, 76, 287-98	5.8	143
225	Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. *Drug Metabolism and Pharmacokinetics*, **2004**, 19, 135-49	2.2	138
224	Human CYP2E1 is regulated by miR-378. *Biochemical Pharmacology*, **2010**, 79, 1045-52	6	133
223	Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. *Mammalian Genome*, **2010**, 21, 427-41	3.2	123
222	MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle. *Journal of Biological Chemistry*, **2010**, 285, 4415-22	5.4	119

221	Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. *Molecular Pharmacology*, **2009**, 76, 702-9	4.3	119
220	Human CYP2A6 is induced by estrogen via estrogen receptor. *Drug Metabolism and Disposition*, **2007**, 35, 1935-41	4	109
219	Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. *Pharmaceutical Research*, **2006**, 23, 1460-72	4.5	109
218	Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. *Clinical Pharmacology and Therapeutics*, **2001**, 69, 72-8	6.1	109
217	Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. *Clinical Pharmacology and Therapeutics*, **2003**, 74, 69-76	6.1	104
216	PPARs regulated by miR-21 and miR-27b in human liver. *Pharmaceutical Research*, **2011**, 28, 2467-76	4.5	102
215	Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. *Drug Metabolism and Disposition*, **2004**, 32, 291-4	4	101
214	Expression of human cytochromes P450 in chimeric mice with humanized liver. *Drug Metabolism and Disposition*, **2004**, 32, 1402-10	4	99
213	Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. *Pharmacogenetics and Genomics*, **2007**, 17, 431-45	1.9	97
212	microRNAs as mediators of drug toxicity. *Annual Review of Pharmacology and Toxicology*, **2013**, 53, 377-400	10.9	94
211	Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. *Toxicology and Applied Pharmacology*, **2013**, 272, 154-60	4.6	91
210	Identification of the cytosolic carboxylesterase catalyzing the 5Sdeoxy-5-fluorocytidine formation from capecitabine in human liver. *Drug Metabolism and Disposition*, **2004**, 32, 1103-10	4	89
209	Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble A levels in a triple transgenic mouse model of AlzheimerS disease (3XTg-AD). *Behavioural Brain Research*, **2015**, 289, 69-77	3.4	87
208	Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. *Journal of Pharmaceutical Sciences*, **2006**, 95, 2673-83	3.9	87
207	Expression of human phase II enzymes in chimeric mice with humanized liver. *Drug Metabolism and Disposition*, **2005**, 33, 1333-40	4	87
206	Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. *Drug Metabolism and Disposition*, **2003**, 31, 589-95	4	86
205	Nicotine metabolism and CYP2A6 allele frequencies in Koreans. *Pharmacogenetics and Genomics*, **2001**, 11, 317-23		83
204	Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. *Biochemical Pharmacology*, **2011**, 82, 1747-56	6	78

203	Chimeric mice with humanized liver. *Toxicology*, **2008**, 246, 9-17	4.4	78
202	Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 319, 693-702	4.7	77
201	Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. *Clinical Pharmacology and Therapeutics*, **2000**, 67, 57-69	6.1	76
200	Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. *British Journal of Clinical Pharmacology*, **2002**, 54, 511-7	3.8	75
199	Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. *Drug Metabolism and Disposition*, **2002**, 30, 155-60	4	75
198	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. *Drug Metabolism and Disposition*, **2002**, 30, 1462-9	4	74
197	Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. *Life Sciences*, **2001**, 70, 471-82	6.8	74
196	Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. *PLoS ONE*, **2012**, 7, e30250	3.7	74
195	Species differences in UDP-glucuronosyltransferase activities in mice and rats. *Drug Metabolism and Disposition*, **2008**, 36, 1745-52	4	71
194	Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. *Drug Metabolism and Pharmacokinetics*, **2005**, 20, 227-35	2.2	71
193	Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. *Toxicological Sciences*, **2005**, 87, 296-305	4.4	69
192	Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. *European Journal of Pharmaceutical Sciences*, **2004**, 22, 419-25	5.1	67
191	Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. *Pharmaceutical Research*, **2000**, 17, 1189-97	4.5	67
190	Toxicological implications of modulation of gene expression by microRNAs. *Toxicological Sciences*, **2011**, 123, 1-14	4.4	66
189	Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers. *American Journal of Physiology - Renal Physiology*, **2007**, 292, G1450-63	5.1	66
188	In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. *Drug Metabolism and Disposition*, **2010**, 38, 2173-8	4	65
187	Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. *Drug Metabolism and Disposition*, **2007**, 35, 747-57	4	65
186	A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. *Clinical Pharmacology and Therapeutics*, **2004**, 76, 519-27	6.1	65

185	Genetic polymorphisms of CYP2C8 in Japanese population. *Drug Metabolism and Disposition*, **2003**, 31, 687-90	4	65
184	Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. *Pharmacogenetics and Genomics*, **2008**, 18, 911-20	1.9	64
183	Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. *Drug Metabolism and Disposition*, **2002**, 30, 636-42	4	63
182	Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. *Drug Metabolism and Disposition*, **2014**, 42, 1103-9	4	62
181	Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. *Drug Metabolism and Disposition*, **2009**, 37, 1513-20	4	60
180	Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. *Chemical Research in Toxicology*, **2008**, 21, 720-5	4	60
179	Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. *Drug Metabolism Reviews*, **2002**, 34, 865-77	7	60
178	In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. *Journal of Pharmaceutical Sciences*, **2007**, 96, 428-37	3.9	58
177	Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. *Drug Metabolism and Disposition*, **2007**, 35, 1781-7	4	58
176	Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. *Journal of Biochemistry*, **2003**, 133, 583-92	3.1	57
175	Halothane-induced liver injury is mediated by interleukin-17 in mice. *Toxicological Sciences*, **2009**, 111, 302-10	4.4	56
174	CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. *International Journal of Cancer*, **2006**, 119, 2520-6	7.5	56
173	Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. *Journal of Clinical Pharmacology*, **2005**, 45, 674-82	2.9	56
172	Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. *Journal of Pharmaceutical Sciences*, **2007**, 96, 1609-18	3.9	55
171	Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. *Toxicology*, **2012**, 293, 107-114	4.4	53
170	MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. *Pharmacology & Therapeutics*, **2011**, 131, 330-7	13.9	53
169	Humanization of excretory pathway in chimeric mice with humanized liver. *Toxicological Sciences*, **2007**, 97, 533-8	4.4	53
168	Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. *Drug Metabolism and Disposition*, **2007**, 35, 1642-8	4	51

167	In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. *Drug Metabolism and Disposition*, **2005**, 33, 754-63	4	51
166	Trans-3Shydroxycotinine O- and N-glucuronidations in human liver microsomes. *Drug Metabolism and Disposition*, **2005**, 33, 23-30	4	51
165	Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2000**, 472, 129-38	3	50
164	Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. *Drug Metabolism and Disposition*, **2010**, 38, 1532-7	4	49
163	Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. *Journal of Biochemistry*, **1999**, 126, 402-7	3.1	49
162	Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5Sdeoxy-5-fluorocytidine formation. *Drug Metabolism and Disposition*, **2004**, 32, 762-7	4	48
161	CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. *Drug Metabolism and Disposition*, **2005**, 33, 1811-8	4	48
160	Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. *Drug Metabolism and Disposition*, **2012**, 40, 671-9	4	47
159	Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. *Toxicological Sciences*, **2012**, 130, 4-16	4.4	46
158	Effects of silver nanoparticles on rat hepatic cytochrome P450 enzyme activity. *Xenobiotica*, **2012**, 42, 854-62	2	46
157	Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. *Drug Metabolism and Disposition*, **2005**, 33, 1202-10	4	46
156	Application of chimeric mice with humanized liver for predictive ADME. *Drug Metabolism Reviews*, **2007**, 39, 145-57	7	45
155	Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities. *Journal of Pharmaceutical Sciences*, **2002**, 91, 952-63	3.9	45
154	Different inhibitory effects in rat and human carboxylesterases. *Drug Metabolism and Disposition*, **2009**, 37, 956-61	4	44
153	A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. *Biochemical Pharmacology*, **2005**, 70, 801-8	6	43
152	Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. *Drug Metabolism and Disposition*, **2011**, 39, 1388-95	4	42
151	Improved highly sensitive method for determination of nicotine and cotinine in human plasma by high-performance liquid chromatography. *Biomedical Applications*, **2000**, 742, 211-5		42
150	Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. *Drug Metabolism and Disposition*, **2013**, 41, 1389-97	4	41

149	A novel duplication type of CYP2A6 gene in African-American population. *Drug Metabolism and Disposition*, **2007**, 35, 515-20	4	41
148	Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. *Drug Metabolism and Disposition*, **2002**, 30, 1484-90	4	41
147	Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes. *Drug Metabolism and Disposition*, **2011**, 39, 54-60	4	39
146	Troglitazone. *Handbook of Experimental Pharmacology*, **2010**, 419-35	3.2	38
145	CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. *Drug Metabolism and Disposition*, **2007**, 35, 335-9	4	37
144	Knock down of gamma-glutamylcysteine synthetase in rat causes acetaminophen-induced hepatotoxicity. *Journal of Biological Chemistry*, **2007**, 282, 23996-4003	5.4	37
143	Novel human CYP2A6 alleles confound gene deletion analysis. *FEBS Letters*, **2004**, 569, 75-81	3.8	37
142	Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. *Toxicology and Applied Pharmacology*, **2012**, 260, 222-31	4.6	36
141	Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. *Toxicology Letters*, **2012**, 214, 9-18	4.4	36
140	Toxicological potential of acyl glucuronides and its assessment. *Drug Metabolism and Pharmacokinetics*, **2017**, 32, 2-11	2.2	35
139	Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. *Toxicology Letters*, **2015**, 236, 16-24	4.4	35
138	Retinoid X receptor □n human liver is regulated by miR-34a. *Biochemical Pharmacology*, **2014**, 90, 179-87	6	35
137	Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. *Biochemical Pharmacology*, **2011**, 81, 289-94	6	35
136	Prilocaine- and lidocaine-induced methemoglobinemia is caused by human carboxylesterase-, CYP2E1-, and CYP3A4-mediated metabolic activation. *Drug Metabolism and Disposition*, **2013**, 41, 1220-30	4	33
135	An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. *Toxicology in Vitro*, **2010**, 24, 1032-8	3.6	33
134	Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. *Journal of Toxicological Sciences*, **2009**, 34 Suppl 2, SP307-12	1.9	33
133	Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. *Drug Metabolism and Disposition*, **2008**, 36, 361-7	4	33
132	Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. *Drug Metabolism and Pharmacokinetics*, **2005**, 20, 121-6	2.2	33

131	Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases. *Frontiers in Pharmacology*, **2016**, 7, 388	5.6	33
130	CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126. *Drug Metabolism and Disposition*, **2015**, 43, 703-12	4	32
129	IL-4 mediates dicloxacillin-induced liver injury in mice. *Toxicology Letters*, **2011**, 200, 139-45	4.4	32
128	Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. *Drug Metabolism and Disposition*, **2012**, 40, 1080-4	4	32
127	N-Glycosylation plays a role in protein folding of human UGT1A9. *Biochemical Pharmacology*, **2010**, 79, 1165-72	6	32
126	Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. *Journal of Pharmaceutical Sciences*, **2010**, 99, 442-54	3.9	32
125	Evaluation and mechanistic analysis of the cytotoxicity of the acyl glucuronide of nonsteroidal anti-inflammatory drugs. *Drug Metabolism and Disposition*, **2014**, 42, 1-8	4	31
124	Metabolic activation of benzodiazepines by CYP3A4. *Drug Metabolism and Disposition*, **2009**, 37, 345-51	4	31
123	Stereoselective glucuronidation of 5-(4Shydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions. *Drug Metabolism and Disposition*, **2007**, 35, 1679-86	4	31
122	Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution. *Drug Metabolism and Disposition*, **2012**, 40, 240-8	4	30
121	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. *Drug Metabolism and Disposition*, **2011**, 39, 838-46	4	30
120	Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. *Drug Metabolism and Disposition*, **2011**, 39, 1345-52	4	29
119	Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. *Drug Metabolism and Pharmacokinetics*, **2007**, 22, 103-12	2.2	29
118	Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney. *Drug Metabolism and Disposition*, **2013**, 41, 1738-43	4	28
117	Interleukin-17 is involved in alpha-naphthylisothiocyanate-induced liver injury in mice. *Toxicology*, **2010**, 275, 50-7	4.4	28
116	Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2). *Biochemical Pharmacology*, **2010**, 79, 288-95	6	28
115	Genetic polymorphisms in the 5Sflanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation. *Pharmacogenetics and Genomics*, **2008**, 18, 709-20	1.9	28
114	Epigenetic regulation of the tissue-specific expression of human UDP-glucuronosyltransferase (UGT) 1A10. *Biochemical Pharmacology*, **2014**, 87, 660-7	6	27

113	Preparation of a specific monoclonal antibody against human UDP-glucuronosyltransferase (UGT) 1A9 and evaluation of UGT1A9 protein levels in human tissues. *Drug Metabolism and Disposition*, **2012**, 40, 1620-7	4	27
112	Th2 cytokine-mediated methimazole-induced acute liver injury in mice. *Journal of Applied Toxicology*, **2012**, 32, 823-33	4.1	27
111	Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4Shydroxyphenyl)-5-phenylhydantoin in human liver microsomes. *Drug Metabolism and Disposition*, **2002**, 30, 1250-6	4	27
110	Carbamazepine-Induced Liver Injury Requires CYP3A-Mediated Metabolism and Glutathione Depletion in Rats. *Drug Metabolism and Disposition*, **2015**, 43, 958-68	4	26
109	Human ∅1hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. *Journal of Biological Chemistry*, **2012**, 287, 9240-9	5.4	26
108	Allosteric kinetics of human carboxylesterase 1: species differences and interindividual variability. *Journal of Pharmaceutical Sciences*, **2008**, 97, 5434-45	3.9	26
107	A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. *Toxicology Letters*, **2016**, 241, 60-70	4.4	25
106	Progesterone receptor membrane component 1 modulates human cytochrome p450 activities in an isoform-dependent manner. *Drug Metabolism and Disposition*, **2011**, 39, 2057-65	4	25
105	In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9. *Drug Metabolism and Pharmacokinetics*, **2009**, 24, 235-44	2.2	24
104	Glucuronidation of antiallergic drug, Tranilast: identification of human UDP-glucuronosyltransferase isoforms and effect of its phase I metabolite. *Drug Metabolism and Disposition*, **2007**, 35, 583-9	4	24
103	Inhibitory effects of neurotransmitters and steroids on human CYP2A6. *Drug Metabolism and Disposition*, **2007**, 35, 508-14	4	24
102	Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6. *Journal of Clinical Pharmacology*, **2006**, 46, 337-44	2.9	24
101	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. *Biological and Pharmaceutical Bulletin*, **2005**, 28, 882-5	2.3	24
100	Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. *Toxicology*, **2005**, 216, 15-23	4.4	24
99	Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. *Toxicology Letters* , **2014**, 228, 13-24	4.4	23
98	P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. *Clinical Cancer Research*, **2014**, 20, 3133-45	12.9	23
97	Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. *Drug Metabolism and Pharmacokinetics*, **2014**, 29, 333-40	2.2	23
96	Estradiol and progesterone modulate halothane-induced liver injury in mice. *Toxicology Letters*, **2011**, 204, 17-24	4.4	23

95	Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. *Journal of Toxicological Sciences*, **2012**, 37, 931-42	1.9	23
94	Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. *Hepatology Research*, **2007**, 37, 548-56	5.1	23
93	Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines. *Toxicological Sciences*, **2005**, 83, 293-302	4.4	23
92	Regulation of cytochrome b5 expression by miR-223 in human liver: effects on cytochrome P450 activities. *Pharmaceutical Research*, **2014**, 31, 780-94	4.5	22
91	Toxicological role of an acyl glucuronide metabolite in diclofenac-induced acute liver injury in mice. *Journal of Applied Toxicology*, **2017**, 37, 545-553	4.1	22
90	Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury. *Journal of Applied Toxicology*, **2012**, 32, 815-22	4.1	22
89	A novel mouse model for phenytoin-induced liver injury: involvement of immune-related factors and P450-mediated metabolism. *Toxicological Sciences*, **2013**, 136, 250-63	4.4	22
88	Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. *Toxicology in Vitro*, **2009**, 23, 1179-87	3.6	22
87	Human hepatocytes can repopulate mouse liver: histopathology of the liver in human hepatocyte-transplanted chimeric mice and toxicologic responses to acetaminophen. *Toxicologic Pathology*, **2008**, 36, 581-91	2.1	22
86	Role of the aryl hydrocarbon receptor and Cyp1b1 in the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Archives of Toxicology*, **2004**, 78, 309-15	5.8	22
85	Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats. *Toxicological Sciences*, **2018**, 166, 228-239	4.4	21
84	Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. *Archives of Toxicology*, **2011**, 85, 199-207	5.8	21
83	Knockdown of superoxide dismutase 2 enhances acetaminophen-induced hepatotoxicity in rat. *Toxicology*, **2009**, 264, 89-95	4.4	21
82	A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity. *Drug Metabolism and Disposition*, **2012**, 40, 1183-90	4	21
81	Drug-induced hepatotoxicity test using gamma-glutamylcysteine synthetase knockdown rat. *Toxicology Letters*, **2009**, 189, 159-65	4.4	21
80	Allyl isothiocyanate (AITC) inhibits pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation and protects against acetaminophen- and amiodarone-induced cytotoxicity. *Archives of Toxicology*, **2015**, 89, 57-72	5.8	20
79	Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays. *Toxicology in Vitro*, **2015**, 30, 241-9	3.6	20
78	Mechanism of exacerbative effect of progesterone on drug-induced liver injury. *Toxicological Sciences*, **2012**, 126, 16-27	4.4	20

77	Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity. *Drug Metabolism and Pharmacokinetics*, **2009**, 24, 226-34	2.2	20
76	Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate. *Japanese Journal of Cancer Research*, **1995**, 86, 985-9		20
75	Involvement of immune- and inflammatory-related factors in flucloxacillin-induced liver injury in mice. *Journal of Applied Toxicology*, **2015**, 35, 142-51	4.1	19
74	Kupffer cell-mediated exacerbation of methimazole-induced acute liver injury in rats. *Journal of Applied Toxicology*, **2016**, 36, 702-15	4.1	19
73	Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. *Drug Metabolism and Pharmacokinetics*, **2006**, 21, 465-74	2.2	19
72	Involvement of oxidative stress and immune- and inflammation-related factors in azathioprine-induced liver injury. *Toxicology Letters*, **2014**, 224, 215-24	4.4	18
71	Key amino acid residues responsible for the differences in substrate specificity of human UDP-glucuronosyltransferase (UGT)1A9 and UGT1A8. *Drug Metabolism and Disposition*, **2009**, 37, 41-6	4	18
70	Change of drug excretory pathway by CCl4-induced liver dysfunction in rat. *Biochemical Pharmacology*, **2007**, 74, 488-95	6	18
69	Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. *Therapeutic Drug Monitoring*, **1999**, 21, 507-13	3.2	18
68	Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD **2009**, 50, 3099-105		17
67	Urinary excretion of phenytoin metabolites, 5-(4Shydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases. *Drug Metabolism and Pharmacokinetics*, **2005**, 20, 135-43	2.2	17
66	Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. *Drug Metabolism and Disposition*, **2015**, 43, 812-8	4	16
65	Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. *Toxicology in Vitro*, **2018**, 48, 286-301	3.6	16
64	Zomepirac Acyl Glucuronide Is Responsible for Zomepirac-Induced Acute Kidney Injury in Mice. *Drug Metabolism and Disposition*, **2016**, 44, 888-96	4	16
63	Involvement of miRNAs in the early phase of halothane-induced liver injury. *Toxicology*, **2014**, 319, 75-84	4.4	16
62	Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries. *Toxicology and Applied Pharmacology*, **2012**, 264, 42-50	4.6	16
61	Establishment of a mouse model for amiodarone-induced liver injury and analyses of its hepatotoxic mechanism. *Journal of Applied Toxicology*, **2016**, 36, 35-47	4.1	16
60	Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. *Biochemical Pharmacology*, **2012**, 84, 1196-206	6	15

59	Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway. *Life Sciences*, **2010**, 87, 537-44	6.8	15
58	Regulation of insulin-like growth factor binding protein-1 and lipoprotein lipase by the aryl hydrocarbon receptor. *Journal of Toxicological Sciences*, **2008**, 33, 405-13	1.9	15
57	Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine. *Pharmacogenetics and Genomics*, **2008**, 18, 761-72	1.9	15
56	Indiplon is hydrolyzed by arylacetamide deacetylase in human liver. *Drug Metabolism and Disposition*, **2014**, 42, 751-8	4	14
55	An orphan esterase ABHD10 modulates probenecid acyl glucuronidation in human liver. *Drug Metabolism and Disposition*, **2014**, 42, 2109-16	4	14
54	A modified multiparametric assay using HepaRG cells for predicting the degree of drug-induced liver injury risk. *Journal of Applied Toxicology*, **2017**, 37, 382-390	4.1	14
53	miRNA in Rat Liver Sinusoidal Endothelial Cells and Hepatocytes and Application to Circulating Biomarkers that Discern Pathogenesis of Liver Injuries. *American Journal of Pathology*, **2018**, 188, 916-928	5.8	13
52	Role of cytochrome P450-mediated metabolism and involvement of reactive metabolite formations on antiepileptic drug-induced liver injuries. *Journal of Toxicological Sciences*, **2018**, 43, 75-87	1.9	13
51	Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. *Clinical Biochemistry*, **2017**, 50, 1034-1039	3.5	13
50	Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. *Cancer Science*, **2010**, 101, 1024-8	6.9	13
49	Identification of urinary biomarkers useful for distinguishing a difference in mechanism of toxicity in rat model of cholestasis. *Basic and Clinical Pharmacology and Toxicology*, **2009**, 105, 156-66	3.1	13
48	A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats. *Toxicology*, **2019**, 415, 26-36	4.4	11
47	Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate. *Toxicology Letters*, **2019**, 307, 49-58	4.4	11
46	Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs. *Drug Metabolism and Pharmacokinetics*, **2012**, 27, 621-30	2.2	11
45	Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. *Toxicology Letters*, **2018**, 291, 184-193	4.4	10
44	Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors. *Experimental and Toxicologic Pathology*, **2016**, 68, 27-38		9
43	Changes in the expression of miRNAs at the pericentral and periportal regions of the rat liver in response to hepatocellular injury: comparison with the changes in the expression of plasma miRNAs. *Toxicology*, **2014**, 322, 89-98	4.4	9
42	Dephosphorylation of ribosomal protein P0 in response to troglitazone-induced cytotoxicity. *Toxicology Letters*, **2006**, 166, 189-99	4.4	9

41	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. *Archives of Toxicology*, **2021**, 95, 149-168	5.8	9
40	Establishment of a novel mouse model for pioglitazone-induced skeletal muscle injury. *Toxicology*, **2017**, 382, 1-9	4.4	8
39	MicroRNA-mediated Th2 bias in methimazole-induced acute liver injury in mice. *Toxicology and Applied Pharmacology*, **2016**, 307, 1-9	4.6	8
38	Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early phase biomarkers for SOS. *Archives of Toxicology*, **2018**, 92, 2947-2962	5.8	8
37	N-Glycosylation during translation is essential for human arylacetamide deacetylase enzyme activity. *Biochemical Pharmacology*, **2014**, 87, 352-9	6	8
36	Inhibition of cytochrome P450 2C9 expression and activity in vitro by allyl isothiocyanate. *Planta Medica*, **2014**, 80, 1097-106	3.1	8
35	Interpretation of the effects of protein kinase C inhibitors on human UDP-glucuronosyltransferase 1A (UGT1A) proteins in cellulo. *Drug Metabolism and Pharmacokinetics*, **2011**, 26, 256-65	2.2	8
34	In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. *Drug Metabolism and Disposition*, **2011**, 39, 1303-10	4	8
33	Inhibitory effects of Kampo medicine on human UGT2B7 activity. *Drug Metabolism and Pharmacokinetics*, **2009**, 24, 490-9	2.2	8
32	Decreased responsiveness of naturally occurring mutants of human estrogen receptor alpha to estrogens and antiestrogens. *Journal of Steroid Biochemistry and Molecular Biology*, **2006**, 100, 79-86	5.1	8
31	Models of Idiosyncratic Drug-Induced Liver Injury. *Annual Review of Pharmacology and Toxicology*, **2021**, 61, 247-268	17.9	8
30	Evaluation of expression and glycosylation status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel specific UGT1A10 monoclonal antibody. *Drug Metabolism and Disposition*, **2017**, 45, 1027-1034	4	7
29	Binding of steroidogenic factor-1 to the regulatory region might not be critical for transcriptional regulation of the human CYP1B1 gene. *Journal of Biochemistry*, **2006**, 139, 527-34	3.1	7
28	Simultaneous measurement of gene expression for hepatotoxicity in thioacetamide-administered rats by DNA microarrays. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2006**, 603, 64-73	3	7
27	Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice. *Chemico-Biological Interactions*, **2018**, 296, 185-197	5	7
26	Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450. *Drug Metabolism and Pharmacokinetics*, **2016**, 31, 210-7	2.2	6
25	Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells. *Journal of Applied Toxicology*, **2016**, 36, 1120-8	4.1	6
24	Cancer pharmacogenomics: achievements in basic research. *International Journal of Clinical Oncology*, **2005**, 10, 14-9	4.2	6

23	Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis. *Laboratory Investigation*, **2017**, 97, 833-842	5.9	5
22	Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background. *Carcinogenesis*, **2019**, 40, 1435-1444	4.6	5
21	Effects of Phyllanthus amarus on the pharmacokinetics of midazolam and cytochrome P450 activities in rats. *Xenobiotica*, **2012**, 42, 641-8	2	5
20	Fluoroquinolones and propionic acid derivatives induce inflammatory responses in vitro. *Cell Biology and Toxicology*, **2018**, 34, 65-77	7.4	4
19	Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism. *Journal of Applied Toxicology*, **2019**, 39, 1541-1556	4.1	4
18	Establishment of MDCKII cell monolayer with metabolic activity by CYP3A4 transduced with recombinant adenovirus. *Drug Metabolism and Pharmacokinetics*, **2013**, 28, 125-31	2.2	4
17	Recent progress in the use of microRNAs as biomarkers for drug-induced toxicities in contrast to traditional biomarkers: A comparative review. *Drug Metabolism and Pharmacokinetics*, **2021**, 37, 100372	2.2	4
16	Acute kidney injury model established by systemic glutathione depletion in mice. *Journal of Applied Toxicology*, **2019**, 39, 919-930	4.1	3
15	Strain and interindividual differences in lamotrigine-induced liver injury in mice. *Journal of Applied Toxicology*, **2019**, 39, 451-460	4.1	3
14	Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development. *Annual Review of Pharmacology and Toxicology*, **2021**,	17.9	3
13	Analysis of a Skeletal Muscle Injury and Drug Interactions in Lovastatin- and Fenofibrate-Coadministered Dogs. *International Journal of Toxicology*, **2019**, 38, 192-201	2.4	2
12	Role of cytochrome P450-mediated metabolism and identification of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury. *Toxicology Letters*, **2015**, 232, 79-88	4.4	2
11	Macrophage-derived extracellular vesicles regulate concanavalin A-induced hepatitis by suppressing macrophage cytokine production. *Toxicology*, **2020**, 443, 152544	4.4	2
10	Exploration of small RNA biomarkers for testicular injury in the serum exosomes of rats. *Toxicology*, **2020**, 440, 152490	4.4	1
9	Development of mice exhibiting hepatic microsomal activity of human CYP3A4 comparable to that in human liver microsomes by intravenous administration of an adenovirus vector expressing human CYP3A4. *Drug Metabolism and Pharmacokinetics*, **2014**, 29, 296-304	2.2	1
8	MicroRNA: Regulation of P450 and Pharmacogenetics **2014**, 385-401		1
7	Current topics in drug metabolism and drug toxicity. Preface. *Drug Metabolism and Pharmacokinetics*, **2011**, 26, 1-2	2.2	1
6	Pharmacological evidence for the involvement of ryanodine receptors in halothane-induced liver injury in mice. *Toxicology*, **2020**, 443, 152560	4.4	1

5	Neutrophil depletion protects against zomepirac-induced acute kidney injury in mice. *Chemico-Biological Interactions*, **2018**, 279, 102-110	5	1
4	Characterization of human UGT2A3 expression using a prepared specific antibody against UGT2A3. *Drug Metabolism and Pharmacokinetics*, **2019**, 34, 280-286	2.2	0
3	Plasma miR-218a-5p as a biomarker for acute cholestatic liver injury in rats and investigation of its pathophysiological roles. *Journal of Applied Toxicology*, **2021**, 41, 1537-1552	4.1	0
2	A Mechanistic View of Troglitazone Hepatotoxicity299-311		
1	Recent Progress and Prospect of Drug Metabolism/Pharmacokinetics Research Contributing to Drug Development. *Kagaku To Seibutsu*, **2017**, 55, 412-420	0	